cosibelimab + pemetrexed + cisplatin + carboplatin

Cosibelimab + pemetrexed + cisplatin + carboplatin is an investigational four-drug combination for oncology, where **cosibelimab** (a monoclonal anti-PD-L1 antibody) is combined with three established anticancer agents: **pemetrexed** (a multitargeted antifolate, cytotoxic agent that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase, thereby blocking both pyrimidine and purine synthesis[2]), **cisplatin** and **carboplatin** (both platinum-based DNA crosslinking agents interfering with replication and promoting apoptosis[2][3]). Pemetrexed/platinum combinations are commonly used for advanced non-small cell lung cancer and other solid tumors, and the addition of cosibelimab introduces immune checkpoint blockade, enhancing anti-tumor immune response (PD-L1 inhibition mechanism).